| Name | Title | Contact Details |
|---|
Ubi Caritas is a Beaumont, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Cedars-Sinai is a non-profit, academic, community-centric, Level 1 Trauma Center in Los Angeles, California. Recognized internationally, Cedars-Sinai brings together top healthcare professionals collaborating to provide exceptional patient care. A combination of patient satisfaction scores, clinical performance initiatives, excellent medical outcomes, national designations and awards and ongoing research and academic programs have earned Cedars-Sinai a top spot on the Honor Roll in the 2014-15 issue of America`s Best Hospitals by U.S. News and World Report. Out of nearly 5,000 hospitals surveyed for the annual rankings, Cedars-Sinai is among just 17 hospitals nationwide to earn the magazine’s Honor Roll designation. To be named to the Honor Roll, a hospital must be rated among the nation’s top 50 programs in at least six specialties. Cedars-Sinai was ranked in 12 categories, including: Cancer; Cardiology and Heart Surgery; Diabetes and Endocrinology; Ear, Nose and Throat; Gastroenterology and GI Surgery; Geriatrics; Gynecology; Nephrology, Neurology and Neurosurgery; Orthopedics; Pulmonology; and Urology. Cedars-Sinai has also received its fourth consecutive Magnet® recognition for nursing excellence from the American Nurses Credentialing Center (ANCC), becoming the hospital with the longest-running Magnet designation in California. Nationwide, only about 5% of hospitals have earned the four-year Magnet designation. Cedars-Sinai was the first Southern California hospital to earn the Magnet honor in 2000, and one of only six hospitals to receive this designation three times. Studies show that Magnet hospitals tend to have lower mortality and infection rates, as well as higher patient satisfaction and nurse staffing levels.
Clinica Sierra Vista, a non-profit corporation, was created to provide health care to poor, migrant farmworkers who harvest the lush agricultural fields in the southern San Joaquin Valley. Today, Clinica Sierra Vista serves a geographically dispersed, low-moderate-fixed income, ethnically diverse, frontier-rural-urban-migrant-homeless patient population. It has grown to be one of the largest comprehensive migrant/community health center systems in the state.
We launched Absolute Insight in 2016 to empower business users in the healthcare sector, where our clients have used it to alleviate the opioid crisis, curb waste in the healthcare system, and target fraudulent entities. As an industry agnostic platform, we`ve began to expand our service across other verticals, fulfilling our mission to become the global gateway for business users to leverage advanced analytics and artificial intelligence at scale. With a deep understanding of your company`s pain points and a platform that makes advanced analytics truly easy, your business users can create data-driven actionable insights and automated pipelines. As data continues to double every two years, this solution is necessary across all industries. Make your data your best asset, and empower your employees with computational resources and algorithms to free them up to pursue more creative work.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.